Arca
Skip to content

Hepatocellular carcinoma

Drug research and approvals for hepatocellular carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 656 studies of hepatocellular carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 54 drug trials for it since 2013, FDA has 15 approved and 92 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 656
  • Trials authorized in Canada: 54
  • FDA orphan approvals: 15
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 656 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 54; search them all in Canada trials
Apr 30, 2025A phase II study of stride (durvalumab + tremelimumab) with lenvatinib versus stride alone in patients with unresectable hepatocellular carcinoma (stride-hcc)LENVIMA / IMFINZI / IMJUDOCANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing
Apr 7, 2025Radiation therapy followed by durvalumab (medi4736) and tremelimumab and surgery versus radiation therapy followed by surgery for resectable hepatocellular…IMFINZI (DURVALUMAB) / TREMELIMUMABHAMILTON HEALTH SCIENCES CORPORATIONOngoing
Mar 21, 2025A randomized phase 2 study of casdozokitug in combination with toripalimab plus bevacizumab in participants with unresectable and/or locally advanced or…CASDOZOKITUG (SRF388 (CHS-388)) / AVASTIN (BEVACIZUMAB) / TORIPALIMABCoherus BioSciences, Inc.Ongoing
Feb 28, 2025A phase III, randomised, open-label, sponsor-blinded, multicentre study of rilvegostomig in combination with bevacizumab with or without tremelimumab as…IMJUDO / RILVEGOSTOMIG (AZD2936) / AVASTINAstraZeneca Pharmaceuticals LPOngoing
Dec 30, 2024A multicenter, open-label, first-in-human study of tyra-430 in advanced hepatocellular carcinoma and other solid tumors with activating fgf/fgfr pathway…TYRA-430TYRA BIOSCIENCES INC.Ongoing
Dec 13, 2024A multicenter, open label, non-randomized first-in-human phase 1 dose escalation and expansion study to evaluate the safety, tolerability,pharmacokinetics, and…BAY 3547926 / BAY 3547922 / ATEZOLIZUMAB / BEVACIZUMABBayerOngoing
Jul 5, 2023A phase 1 study of incb099280 in combination with ipilimumab in participants with select solid tumorsINCB099280 / IPILIMUMABIncyte CorporationClosed
Apr 4, 2023A phase 1/2 exploratory study of the tbl1 inhibitor, tegavivint (bc2059), in patients with advanced hepatocellular carcinomaTEGAVIVINT (BC2059) / PEMBROLIZUMABITERION THERAPEUTICSPending
Oct 18, 2022Perioperative therapy with durvalumab plus tremelimumab for patients with resectable hepatocellular carcinoma (hcc) - a phase II trial (neotoma)IMFINZI / TREMELIMUMABUNIVERSITY HEALTH NETWORKOngoing
Jun 1, 2022Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond milan criteria: a feasibility studyTECENTRIQ / AVASTINHOUSTON METHODIST RESEARCH INSTITUTEOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 107
Apr 11, 2025Opdivoin combination with ipilimumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma…Bristol-Myers Squibb CompanyApproved
Jan 25, 2024Keytrudatreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a…MSD International Business GmbHApproved
Oct 21, 2022ImfinziIn combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)AstraZeneca Pharmaceuticals LPApproved
Oct 21, 2022ImjudoIn combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)AstraZeneca Pharmaceuticals LPApproved
May 29, 2020Tecentriq and AvastinAVASTIN, in combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have…Genentech, Inc.Approved
May 29, 2020Tecentriq and AvastinTECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have…Genentech, Inc.Approved
Mar 10, 2020OPDIVOOPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC)…Bristol-Myers Squibb CompanyApproved
May 10, 2019CYRAMZACYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein…Eli Lilly and CompanyApproved
Jan 14, 2019CABOMETYXCABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.Exelixis, Inc.Approved
Nov 9, 2018KeytrudaKEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenibMSD International Business GmbHApproved
Aug 15, 2018LENVIMALENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Eisai Inc.Approved
Sep 22, 2017OPDIVOTreatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn)Bristol-Myers Squibb CompanyApproved
Apr 27, 2017StivargaTreatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.Bayer HealthCare Pharmaceuticals, Inc.Approved
Apr 4, 2014LipiodolSelective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)Guerbet LLCApproved
Nov 16, 2007NexavarTreatment of unresectable hepatocellular carcinomaBayer Pharmaceuticals CorporationApproved

Medicines Authorised in the EU

Newest first
Feb 20, 2023ImjudotremelimumabAstraZeneca ABEMA ↗
Nov 9, 2022Sorafenib Accordsorafenib · genericAccord Healthcare S.L.U.EMA ↗
Jul 19, 2006NexavarsorafenibBayer AGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.